WO2006002394A3 - Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response - Google Patents
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response Download PDFInfo
- Publication number
- WO2006002394A3 WO2006002394A3 PCT/US2005/022561 US2005022561W WO2006002394A3 WO 2006002394 A3 WO2006002394 A3 WO 2006002394A3 US 2005022561 W US2005022561 W US 2005022561W WO 2006002394 A3 WO2006002394 A3 WO 2006002394A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- herpes simplex
- simplex virus
- avirulent
- present
- oncolytic herpes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58271404P | 2004-06-24 | 2004-06-24 | |
US60/582,714 | 2004-06-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006002394A2 WO2006002394A2 (en) | 2006-01-05 |
WO2006002394A3 true WO2006002394A3 (en) | 2006-06-08 |
Family
ID=35782372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/022561 WO2006002394A2 (en) | 2004-06-24 | 2005-06-24 | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
Country Status (2)
Country | Link |
---|---|
US (3) | US7731952B2 (en) |
WO (1) | WO2006002394A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7038065B2 (en) | 2016-01-08 | 2022-03-17 | レプリミュン リミテッド | Oncolytic virus strain |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
WO2008009115A1 (en) * | 2006-07-18 | 2008-01-24 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
US20120237481A1 (en) * | 2011-03-17 | 2012-09-20 | Xiaoliu Zhang | Incorporation of the B18R gene to enhance antitumor effect of virotherapy |
ES2704632T3 (en) * | 2011-09-08 | 2019-03-19 | Univ New York | Oncolytic herpes simplex virus and its therapeutic uses |
US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
MA39818A (en) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof |
JP6625627B2 (en) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using the same |
EA201791382A1 (en) | 2014-12-18 | 2017-10-31 | Эмджен Инк. | STABLE DRUG FORM OF FROZEN VIRUS OF SIMPLE HERPES |
US10967015B2 (en) | 2015-06-15 | 2021-04-06 | New York University | Method of treatment using oncolytic viruses |
KR20230051601A (en) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos ligand variant immunomodulatory proteins and uses thereof |
WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
EP3872180A1 (en) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
EP3580341A4 (en) | 2017-02-09 | 2020-11-04 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
CN115820571A (en) * | 2017-03-09 | 2023-03-21 | 厦门大学 | Recombinant herpes simplex virus and application thereof |
MX2019010797A (en) | 2017-03-15 | 2019-10-24 | Amgen Inc | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer. |
BR112019018747A2 (en) | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | variant immunomodulatory proteins of cd80 and uses thereof |
AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
DK3596116T3 (en) | 2017-03-16 | 2023-11-27 | Alpine Immune Sciences Inc | VARIANT IMMUNE MODULATORY PD-L1 PROTEINS AND USES THEREOF |
HUE058233T2 (en) | 2017-08-03 | 2022-07-28 | Amgen Inc | Interleukin-21 muteins and methods of treatment |
AU2018314227A1 (en) | 2017-08-07 | 2020-02-06 | Amgen Inc. | Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus |
SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
AU2018351000B2 (en) | 2017-10-18 | 2023-11-30 | Alpine Immune Sciences, Inc. | Variant ICOS Ligand immunomodulatory proteins and related compositions and methods |
CR20200330A (en) | 2018-01-12 | 2020-12-23 | Amgen Inc | Anti-pd-1 antibodies and methods of treatment |
JP7379385B2 (en) | 2018-06-04 | 2023-11-14 | カリディ・バイオセラピューティクス・インコーポレイテッド | Cell-based vehicles to enhance viral therapy |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
CN109161561A (en) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | A kind of the novel oncolytic virus and its construction method of selectively killing prostate gland cancer cell |
WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
AU2019377141A1 (en) | 2018-11-06 | 2021-05-20 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
WO2020107002A2 (en) | 2018-11-21 | 2020-05-28 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
TW202038947A (en) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses |
JP2022510276A (en) | 2018-11-30 | 2022-01-26 | アルパイン イミューン サイエンシズ インコーポレイテッド | CD86 variant immunomodulatory protein and its use |
TW202039835A (en) | 2018-12-27 | 2020-11-01 | 美商安進公司 | Lyophilized virus formulations |
WO2020163703A1 (en) * | 2019-02-08 | 2020-08-13 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
CN113748124A (en) | 2019-02-27 | 2021-12-03 | 阿克蒂姆治疗有限公司 | Immunostimulatory bacteria engineered to colonize tumors, tumor resident immune cells, and tumor microenvironment |
JP2022522817A (en) | 2019-03-05 | 2022-04-20 | アムジエン・インコーポレーテツド | Use of oncolytic virus to treat cancer |
TW202102543A (en) | 2019-03-29 | 2021-01-16 | 美商安進公司 | Use of oncolytic viruses in the neoadjuvant therapy of cancer |
AU2021258194A1 (en) | 2020-04-22 | 2022-11-24 | Indapta Therapeutics, Inc. | Natural killer (NK) cell compositions and methods for generating same |
CA3203135A1 (en) * | 2020-12-04 | 2022-06-09 | Immvira Co., Limited | Oncolytic herpes simplex type 1 viruses for treatment of brain tumors |
TW202241479A (en) | 2020-12-30 | 2022-11-01 | 美商安迅生物製藥公司 | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
CN115537404B (en) * | 2021-12-22 | 2023-10-20 | 河南省人民医院 | Type I herpes simplex virus strain with potential anti-tumor effect and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824318A (en) * | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769331A (en) * | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US5288641A (en) * | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US4859587A (en) * | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
CA1282721C (en) * | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
US6610287B1 (en) * | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
US5328688A (en) * | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
US6537541B1 (en) * | 1990-09-14 | 2003-03-25 | The General Hospital Corporation | Implantation of HSV-TK retrovirus producer cells to destroy glioma |
US6770274B1 (en) * | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
US6555108B1 (en) * | 1990-09-14 | 2003-04-29 | The General Hospital Corporation | Implanting HSV-TK retrovirus producing cells to treat tumors |
DK0675961T3 (en) * | 1992-03-31 | 2003-03-24 | Arch Dev Corp | Treatment of tumorigenic disease with a modified HSV |
US5334498A (en) * | 1992-08-18 | 1994-08-02 | Arch Development Corporation | Herpes simplex virus 1 UL13 gene product: methods and compositions |
US6139834A (en) * | 1994-06-23 | 2000-10-31 | Georgetown University | Replication-competent Herpes simplex virus mediates destruction of neplastic cells |
US5585096A (en) * | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US6699468B1 (en) * | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) * | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US5922328A (en) * | 1995-09-11 | 1999-07-13 | Aviron | Methods and compositions for treatment of HSV-2 infections and conditions |
US5876923A (en) * | 1996-07-26 | 1999-03-02 | Arch Development Corporation | Herpes simplex virus ICP4 as an inhibitor of apoptosis |
US5846948A (en) * | 1996-08-30 | 1998-12-08 | Arch Development Corporation | Herpes simplex virus ORF P is a repressor of viral protein synthesis |
US6218103B1 (en) * | 1997-04-16 | 2001-04-17 | Arch Development Corporation | Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis |
US5998174A (en) * | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
US20040151697A1 (en) * | 1998-01-08 | 2004-08-05 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
JP4623832B2 (en) * | 1999-02-05 | 2011-02-02 | アーチ デベロップメント コーポレイション | Treatment of tumors with genetically engineered herpesviruses |
WO2001077394A1 (en) * | 2000-04-10 | 2001-10-18 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
JP4004952B2 (en) * | 2000-11-28 | 2007-11-07 | ザ ユニヴァーシティ オヴ シカゴ | Genetically engineered herpesvirus for the treatment of cardiovascular disease |
AU2002306919B2 (en) * | 2001-03-27 | 2007-11-22 | Tomoki Todo | Viral vectors and their use in therapeutic methods |
US20050048491A1 (en) * | 2001-10-09 | 2005-03-03 | WEICHSELBAUM Ralph R. | Methods and kits for use in selecting approaches to treating cancer |
US7592169B2 (en) * | 2003-04-25 | 2009-09-22 | Medimmune, Llc | Methods and compositions for treatment and prevention of HSV-2 infections and conditions |
-
2005
- 2005-06-24 WO PCT/US2005/022561 patent/WO2006002394A2/en active Application Filing
- 2005-06-24 US US11/166,438 patent/US7731952B2/en active Active
-
2010
- 2010-04-27 US US12/767,973 patent/US8252277B2/en active Active
-
2012
- 2012-07-30 US US13/561,823 patent/US8709397B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824318A (en) * | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
Non-Patent Citations (2)
Title |
---|
MERKERT J M ET AL: "Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignent glioma: results of a phase 1 trial.", GENE THER., vol. 7, May 2000 (2000-05-01), pages 867 - 874 * |
MOHR I.: "Genetic metamorphisis of herpes simplex virus-1 into a biological therapeutic for human cancer.", EXPERT OPINION BIOL THER., vol. 3, no. 1, February 2003 (2003-02-01), pages 113 - 125, XP009184549 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7038065B2 (en) | 2016-01-08 | 2022-03-17 | レプリミュン リミテッド | Oncolytic virus strain |
Also Published As
Publication number | Publication date |
---|---|
US20060039894A1 (en) | 2006-02-23 |
US8709397B2 (en) | 2014-04-29 |
US8252277B2 (en) | 2012-08-28 |
US7731952B2 (en) | 2010-06-08 |
US20110236415A1 (en) | 2011-09-29 |
WO2006002394A2 (en) | 2006-01-05 |
US20130034586A1 (en) | 2013-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006002394A3 (en) | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response | |
Manservigi et al. | HSV recombinant vectors for gene therapy | |
Watanabe et al. | Oncolytic virotherapy by HSV | |
CN108570455B (en) | Recombinant herpes simplex virus and application thereof | |
Frazer et al. | Prevention and treatment of papillomavirus-related cancers through immunization | |
JP2003520044A5 (en) | ||
JP2022037134A (en) | Herpes simplex virus vaccine | |
JP2006528484A5 (en) | ||
KR20180094859A (en) | Nucleic acid vaccine for varicella zoster virus (VZV) | |
US20060093620A1 (en) | Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods | |
WO2002092827A3 (en) | Corona-virus-like particles comprising functionally deleted genomes | |
CA2475604A1 (en) | An herpes simplex virus complex | |
Krishnan et al. | Developments in vaccination for herpes simplex virus | |
Pourchet et al. | CD8+ T-cell immune evasion enables oncolytic virus immunotherapy | |
JP5845191B2 (en) | Herpes simplex virus vaccine | |
Leddon et al. | Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity | |
WO2014036807A1 (en) | Recombinant herpes simplex virus, preparation method therefor and application thereof | |
Nguyen et al. | The current state of oncolytic herpes simplex virus for glioblastoma treatment | |
Worschech et al. | The immunologic aspects of poxvirus oncolytic therapy | |
WO2007005876A3 (en) | Chimeric herpes viruses and uses thereof | |
Zaitseva et al. | Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus | |
Jiang et al. | CRM197-conjugated multi antigen dominant epitope for effective human cytomegalovirus vaccine development | |
JP5522884B2 (en) | Anti-cancer effect enhancer for viral therapy, cancer prevention or treatment method | |
Loudon et al. | Preclinical safety testing of DISC‐hGMCSF to support phase I clinical trials in cancer patients | |
EP3594328A1 (en) | Recombinant herpes simplex virus and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05789194 Country of ref document: EP Kind code of ref document: A2 |